CN113662858A - Intelligent medicine taking prompting system and method - Google Patents
Intelligent medicine taking prompting system and method Download PDFInfo
- Publication number
- CN113662858A CN113662858A CN202110999931.7A CN202110999931A CN113662858A CN 113662858 A CN113662858 A CN 113662858A CN 202110999931 A CN202110999931 A CN 202110999931A CN 113662858 A CN113662858 A CN 113662858A
- Authority
- CN
- China
- Prior art keywords
- medicine
- mood
- intelligent
- patient
- taking
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 266
- 238000000034 method Methods 0.000 title claims description 11
- 206010026749 Mania Diseases 0.000 claims abstract description 36
- 239000004050 mood stabilizer Substances 0.000 claims abstract description 35
- 229940127237 mood stabilizer Drugs 0.000 claims abstract description 34
- 230000001430 anti-depressive effect Effects 0.000 claims abstract description 33
- 239000000935 antidepressant agent Substances 0.000 claims abstract description 32
- 229940005513 antidepressants Drugs 0.000 claims abstract description 32
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 22
- 238000013268 sustained release Methods 0.000 claims abstract description 22
- 239000012730 sustained-release form Substances 0.000 claims abstract description 22
- 239000000164 antipsychotic agent Substances 0.000 claims abstract description 19
- 230000036651 mood Effects 0.000 claims abstract description 19
- 230000000561 anti-psychotic effect Effects 0.000 claims abstract description 14
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 11
- 239000011248 coating agent Substances 0.000 claims abstract description 4
- 238000000576 coating method Methods 0.000 claims abstract description 4
- 238000002360 preparation method Methods 0.000 claims abstract description 4
- 229940079593 drug Drugs 0.000 claims description 45
- 208000020925 Bipolar disease Diseases 0.000 claims description 21
- 239000006187 pill Substances 0.000 claims description 13
- 230000003001 depressive effect Effects 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 8
- 239000003086 colorant Substances 0.000 claims description 3
- 230000000994 depressogenic effect Effects 0.000 claims description 3
- 230000007935 neutral effect Effects 0.000 claims description 2
- 238000002483 medication Methods 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 abstract description 17
- 208000017194 Affective disease Diseases 0.000 abstract description 16
- 201000010099 disease Diseases 0.000 abstract description 9
- 239000000203 mixture Substances 0.000 abstract description 5
- 230000001544 dysphoric effect Effects 0.000 abstract 1
- 230000006399 behavior Effects 0.000 description 22
- 206010000117 Abnormal behaviour Diseases 0.000 description 14
- 230000008859 change Effects 0.000 description 7
- 238000012544 monitoring process Methods 0.000 description 7
- 230000002159 abnormal effect Effects 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 230000008451 emotion Effects 0.000 description 6
- 230000009471 action Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000002996 emotional effect Effects 0.000 description 5
- 238000012795 verification Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000003340 mental effect Effects 0.000 description 4
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 206010012374 Depressed mood Diseases 0.000 description 3
- 208000004547 Hallucinations Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000004891 communication Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 description 3
- 229960005017 olanzapine Drugs 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 208000020401 Depressive disease Diseases 0.000 description 2
- GIYXAJPCNFJEHY-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]-1-propanamine hydrochloride (1:1) Chemical compound Cl.C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 GIYXAJPCNFJEHY-UHFFFAOYSA-N 0.000 description 2
- 230000016571 aggressive behavior Effects 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 230000003028 elevating effect Effects 0.000 description 2
- 229960000389 fluoxetine hydrochloride Drugs 0.000 description 2
- 229960001848 lamotrigine Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000006996 mental state Effects 0.000 description 2
- 230000006855 networking Effects 0.000 description 2
- 229960004431 quetiapine Drugs 0.000 description 2
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 2
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 206010001488 Aggression Diseases 0.000 description 1
- 206010002652 Anorgasmia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010048909 Boredom Diseases 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 206010043268 Tension Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 208000012761 aggressive behavior Diseases 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 208000022257 bipolar II disease Diseases 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960004170 clozapine Drugs 0.000 description 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000004047 hyperresponsiveness Effects 0.000 description 1
- 230000001505 hypomanic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229940072170 lamictal Drugs 0.000 description 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
- 229910052808 lithium carbonate Inorganic materials 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940023568 magnesium valproate Drugs 0.000 description 1
- LKLLHOIUJVEAGU-UHFFFAOYSA-L magnesium;2-propylpentanoate Chemical compound [Mg+2].CCCC(C([O-])=O)CCC.CCCC(C([O-])=O)CCC LKLLHOIUJVEAGU-UHFFFAOYSA-L 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000008897 memory decline Effects 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 238000012806 monitoring device Methods 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 238000003909 pattern recognition Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000001107 psychogenic effect Effects 0.000 description 1
- ZTHJULTYCAQOIJ-WXXKFALUSA-N quetiapine fumarate Chemical compound [H+].[H+].[O-]C(=O)\C=C\C([O-])=O.C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12.C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 ZTHJULTYCAQOIJ-WXXKFALUSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229960001534 risperidone Drugs 0.000 description 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
- 229940035004 seroquel Drugs 0.000 description 1
- 229940084026 sodium valproate Drugs 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 230000003019 stabilising effect Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 201000009032 substance abuse Diseases 0.000 description 1
- 231100000736 substance abuse Toxicity 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 229940034173 symbyax Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229940102566 valproate Drugs 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
- A61J7/04—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers
- A61J7/0409—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers with timers
- A61J7/0418—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers with timers with electronic history memory
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/16—Devices for psychotechnics; Testing reaction times ; Devices for evaluating the psychological state
- A61B5/165—Evaluating the state of mind, e.g. depression, anxiety
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4842—Monitoring progression or stage of a disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
- A61B5/6801—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be attached to or worn on the body surface
- A61B5/6802—Sensor mounted on worn items
- A61B5/681—Wristwatch-type devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/74—Details of notification to user or communication with user or patient ; user input means
- A61B5/746—Alarms related to a physiological condition, e.g. details of setting alarm thresholds or avoiding false alarms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
- A61J7/04—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers
- A61J7/0409—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers with timers
- A61J7/0454—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers with timers for dispensing of multiple drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J2200/00—General characteristics or adaptations
- A61J2200/70—Device provided with specific sensor or indicating means
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medical Informatics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Psychiatry (AREA)
- Pharmacology & Pharmacy (AREA)
- Physiology (AREA)
- Child & Adolescent Psychology (AREA)
- Developmental Disabilities (AREA)
- Educational Technology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Social Psychology (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Abstract
The invention provides an intelligent medicine taking prompting system, which comprises a medicine composition for treating bipolar affective disorder and a medicine composition taking prompting system for matching with a disease period of the bipolar affective disorder, wherein the medicine composition comprises one or more of three medicine taking windows, and the medicine taking windows comprise a mood stabilizer for manic or dysphoric stage, an antidepressant or antipsychotic agent for depression stage or a sustained-release agent for intermittent stage. The mood stabilizer is provided with an edible overcoat which comprises one or more of color systems P, PB, B, BG or G on the outer surface of part or all of the outer surface of the mood stabilizer so as to resist the conflict psychology of taking the medicine during the manic period; an antidepressant or antipsychotic preparation for resisting passive mood of a patient is prepared by coating the external surface of the preparation with a coating consisting of GY, Y, TR, R or RP.
Description
Technical Field
The invention relates to the field of medical machinery, in particular to an intelligent medicine taking prompt system and method.
Background
Bipolar disorder (BPD) is a mood disorder with mania and depression, a chronic circulatory disorder. According to DSM-IV, bipolar disorder is classified into type I bipolar disorder, type II bipolar disorder, circulatory disorder and bipolar disorder not otherwise classified. When a patient experiences more than one manic episode or a mixed episode in which depressive episodes and manic episodes occur simultaneously, he/she is diagnosed with type I bipolar disorder. Bipolar II disorder refers to a condition in which a patient with a history of at least one major depressive episode further experiences at least one hypomanic episode (American Psychiatric Association, 2000). Furthermore, the clinical manifestations of patients with bipolar affective disorder are extremely complex, with low or high mood, repeated, alternating, irregular presentation, accompanied by disorganized symptoms such as distraction, low rate, exaggeration, thinking and escaping, hyperresponsiveness, sleep reduction, and speech increase. Anxiety, obsessive-compulsive disorder, substance abuse, and psychogenic symptoms such as hallucinations, delusions, or tenseness are also common. The course of the disease is more or less polymorphic, paroxysmal, cyclic, mixed migratory, and tidal falling, such as 3 depressive phases followed by 2 manic phases. The intermittent period is long or short, the social function is relatively normal in the intermittent period, but the social function can be damaged, and the conditions of quick attack frequency and more complex disease condition appear after repeated attacks. Therefore, in clinical treatment, doctors often need to use multiple drugs in combination, and the drugs for inhibiting the heightened emotion and the drugs for increasing the emotional enthusiasm are alternately selected. Some patients need to take multiple medicines separately in multiple time periods in daily life to ensure physical health, but the patients often miss or forget the medicine taking time due to busy affairs or memory decline of the patients. Based on the above, the reminding medicine box is a personal health care product which appears along with the continuous improvement of the health concept of people and the transformation of life style and life rhythm. The problem of how to take the medicine, take the medicine well, forget to take the medicine and not take the medicine by mistake is followed-the medicine box is reminded to be just listed under the actual requirement of the market.
The medicine is taken separately in multiple time periods of the medicine class, the taking time, the taking dosage, the taking sequence and the like of the multiple medicines are required to be paid attention to, once the taking information is misjudged, the medicines are disabled, and if the taking information is wrong, the medicines have negative effects on the body, so that the mental diseases are aggravated, and mania and overstrain are induced.
Chinese patent with publication number CN105708689B relates to an intelligent medicine box that possesses automatic function is reminded in dispensing and monitoring, belong to the medical instrument field, including the medicine box, the upper end of medicine box is connected with the medicine storehouse, the inside medicine bowl that is provided with the telescopic of lower extreme of medicine box, the medicine storehouse includes medicine storehouse casing and medicine storehouse inner bag, the bottom of medicine storehouse inner bag is provided with vibrating motor, the medicine storehouse inner bag is provided with out medicine passageway and medicine storage room, medicine storehouse inner bag top is provided with the medicine storehouse steering wheel, medicine storehouse steering wheel both sides are connected with outer baffle and inner baffle, still be provided with medicine retention monitoring devices in the medicine box, medicine counting assembly, control module, the module is reminded to the reputation, networking communication module, intelligent medicine box passes through networking communication module and server communication, server UNICOM user program end. The device sets up to a plurality of medicine storehouses, realizes out the medicine through the cooperation of slope passageway and vibration, nevertheless because the setting of a plurality of medicine storehouses, the user sets up the medicine storehouse position that the medicine of treating is placed in based on the same appearance of a plurality of medicine storehouses very difficult discernment when using.
Based on the resolution of the positions of medicine bins for storing medicines, Chinese patent with publication number CN211132165U discloses an intelligent reminding medicine box based on a lifting device, and relates to the field of intelligent medicine boxes; the box body comprises a box body, a control unit, an acousto-optic reminding unit, a lifting device, an input unit and N small medicine box bodies, wherein N cylindrical holes used for placing and fixing the small medicine box bodies are formed in the box body, the lifting device comprises a steering engine and a rocker arm, the acousto-optic reminding unit, the lifting device, the input unit and the steering engine are respectively electrically connected with the control unit, a gear set of the steering engine is rotatably connected with the rocker arm, and the rocker arm is installed at the bottom of the small medicine box bodies. Based on the warning to the patient of taking medicine of the article class, set up elevating gear and realize the dual function that the medicine was indicateed and was dosed, nevertheless elevating gear structure is complicated, and the very easy unable lift that breaks down, the lift process needs time and space simultaneously, and the device reachs the suggestion time and goes up and down the in-process and need reasonable space, requires very high to the user, portable not convenient to. Chinese patent with publication number CN101617992B provides a medicine taking reminding device with a divided box medicine box, which comprises a housin, be equipped with two at least divided box medicine boxes of putting medicine check, correspond the lid of seting up a mouth of falling the medicine with putting the medicine check, the timing alarm is installed on the casing, the protruding pivot that forms in casing center, divided box nestification is equipped with actuating mechanism in the casing and the suit is in the pivot, be equipped with actuating mechanism between casing and divided box medicine box, travel switch, actuating mechanism drives divided box and rotates in the pivot of casing, travel switch controls the turned angle of divided box, actuating mechanism, travel switch and timing alarm electric connection. The device is used for providing the medicine in a timing and directional mode through system rotation control, but the device is not set according to the posture of taking the medicine under different patient states of the patient state of illness.
Therefore, various drugs have been used to treat or prevent bipolar disorder, but their use still has limitations due to unsatisfactory levels of drug response or side effects. Therefore, there is a need for new drugs for bipolar disorder with improved efficacy and less side effects.
Furthermore, on the one hand, due to the differences in understanding to the person skilled in the art; on the other hand, since the inventor has studied a lot of documents and patents when making the present invention, but the space is not limited to the details and contents listed in the above, however, the present invention is by no means free of the features of the prior art, but the present invention has been provided with all the features of the prior art, and the applicant reserves the right to increase the related prior art in the background.
Disclosure of Invention
Aiming at the defects of the prior art, the invention designs an intelligent medicine taking prompting system, which comprises a medicine composition for treating the bipolar affective disorder and a medicine composition taking prompting system for matching the disease period of the bipolar affective disorder, wherein the intelligent medicine taking prompting system provides medicine taking suggestions with color systems as distinguishing characteristics of a mood stabilizer, an antidepressant or antipsychotic medicament and a sustained-release medicament for a user in an image mode, and the taking sequence of the mood stabilizer, the antidepressant or antipsychotic medicament and the sustained-release medicament forms an execution condition of a message-driven medicine taking suggestion which is processed and developed by the intelligent medicine taking prompting system around the distinguishing characteristic color systems as information. The pharmaceutical composition comprises one or more of three dosing windows comprising a mood stabilizer for manic or manic phases, an antidepressant or antipsychotic agent for depressive phases or a sustained release agent for intermittent phases. The mood stabilizer is provided with an edible overcoat which comprises one or more of color systems P, PB, B, BG or G on the outer surface of part or all of the outer surface of the mood stabilizer so as to resist the conflict psychology of taking the medicine during the manic period; an antidepressant or antipsychotic agent for resisting passive mood of medicine is provided, and the outer surface of the agent is provided with a coat formed by one or more colors of GY, Y, TR, R or RP; a sustained-release agent whose sustained-release outer film is set in a transparent color, white, black or a neutral hue with a certain gradation in a manner distinguishable from a mood stabilizer and an antidepressant or antipsychotic agent.
According to a preferred embodiment, the color series P, PB, B, BG or G can have a hue of not less than 120 °.
The technical scheme has the advantages that: the prior art traditional Chinese medicine pills are mostly white or black in color, the pathogenesis of the bipolar affective disorder determines that a patient must take a medicament for a manic period and a medicament for a depression period in the morbidity period, a patient with the bipolar affective disorder also needs to take a sustained-release medicament for preventing the next cycle in an intermittent period, and even the types of the three medicaments taken in the cycle are not limited to one. Because the patient is easy to generate behavior such as rage, mania or hallucination which influences the medicine taking process in the disease stage, the same-color pills can still cause the patient to generate cognitive disorder even if being placed at different positions.
In psychology of color, it is considered that the emotion of a human body is affected by a change in color, thereby proposing a cool tone that is cool and quiet and a warm tone that is warm. The difference of the cold and warm tones is not only the comfort to the human mind, but also the obvious difference of the cold and warm tones which can be seen by naked eyes.
In the present embodiment, the cool tone and the warm tone are distinguished by a 24-phase ring as shown in fig. 1. The cool tone is applied to the surface of the medicament of a patient treating the manic cycle, so that the cool tone medicament is comfortable and has more positive medicament taking effect when the patient visually observes the medicament. The warm tone is applied to the surface of the medicament for treating patients with depression periods, and when the patients resist the medicament due to low mood, the medicament in the warm tone system can attract the attention of the patients and induce the patients to take the medicament in a mode of generating positive and positive guiding effect on human psychology. Further, the difference in the cool and warm tones enables patients and patient guardians to distinguish between drugs used to treat manic and depressive periods even when the drugs are intentionally or unintentionally mixed together by the patient during the visual observation, avoiding wasting the drugs. The appeal of cold and warm tones to patients in different periods of illness is also different, and even if the drugs are mixed, patients in mania still have more positive picking up intention on cold-colored pills, and patients in depression still have more positive picking up interest on warm-colored drugs. Based on the purpose of distinguishing pills in different periods, the slow release medicament taken by the patient with intermission period and relatively normal emotional state can be set to be more common or more popular white, black or gray, so that the patient in the normal period can adapt to the medicine taking process.
Patients with bipolar affective disorder develop extreme emotions alternately appearing in a manic stage and a depressive stage at least in a specific time period, lack self-management ability along with the generation of the extreme emotions, and cannot evaluate and predict self behaviors by themselves; the treatment of the disease not only needs the management and control of drug measures, but also needs the training of behavior management. The personal emotional management disorder of the caregivers of the bipolar affective disorder patients due to long-term care often constitutes a key problem in the care of the bipolar affective disorder patients. At present, the means of assisting treatment by intelligent equipment without emotion and emotional feedback becomes a common technical measure, but patients and family members lack learning interest and even show extreme boredom to the intelligent equipment without emotion and emotional feedback, so that the means are not recognized. In view of the above, the present invention is intended to realize the medication measures which patients and caregivers must face by the apparatus and the program carried by the apparatus in a manner of developing the habit of the patients to develop specific medication behaviors by designing a special apparatus, and to make the medication measures which patients and caregivers must face regularly appear due to the fact that the apparatus is not affected by the fluctuation of "mood". By means of the taking training of the mood stabilizer, the antidepressant or antipsychotic medicament and the sustained-release medicament which generate positive promoting effects on mood rising and falling among the mood stabilizer, the antidepressant or antipsychotic medicament and the sustained-release medicament so as to mutually promote the medicinal effects of the mood stabilizer, the antidepressant or antipsychotic medicament and the sustained-release medicament and form the conditions of the taking conditions, the independent patients can be better treated and the behavior characteristics are optimized. Therefore, the taking scheme of the mood stabilizer, the antidepressant or antipsychotic agent and the sustained-release agent which are mutually restricted in time and have strict requirements on color series is specially selected, a compromise scheme is found between complex and precise behavior treatment, and the taking scheme can be accepted and used by most patients through extensive tests. The mood stabilizer, the antidepressant or antipsychotic medicament and the sustained-release medicament are arranged in the form of the medicine wrappers with obvious differences, so that the mood stabilizer, the antidepressant or antipsychotic medicament and the sustained-release medicament are obviously different in taking mode, particularly the mood stabilizer is taken in the form of the medicine wrapper depending on the cold color system of the mood stabilizer, the medicine wrapper is different from the warm color system of the antidepressant or antipsychotic medicament, and the image acquisition mode is enough to distinguish the mood stabilizer, the antidepressant or antipsychotic medicament and the sustained-release medicament. Therefore, the medicine storage system does not need a large amount of high-precision data analysis and behavior pattern recognition, does not need a complex and expensive biosensor, and is particularly suitable for families of mental patients with extremely high disease-causing poverty rate.
According to a preferred embodiment, the mood stabilizer coating comprises a pattern for calming mood based on its disposition against a manic or manic mood of the patient consisting of one or several of the color families P, PB, B, BG or G. The overcoat of antidepressant or antipsychotic agents is based on its setting of a pattern for mood enhancement or attention-arousal consisting of one or several of the color systems GY, Y, TR, R or RP for a patient's depressed or fantasy mood.
The technical scheme has the advantages that: the medicament wrap can be arranged in different patterns based on the selection of its color for the purpose of enhancing the appeal of the medicament wrap to patients in different periods of illness and assisting the medicament compound in smoothing the mood of the patient. Preferably, the pattern of the mood stabilizer is set to meet a pattern that is suitable for matching with one or more of the color systems P, PB, B, BG or G and that gives a calm and cool cue to a person in daily life, such as the sea. The pattern of antidepressant or antipsychotic agents needs to mobilize the human body's motivation and draw attention from the patient who resists the medication intake, which can be set to flames or the sun.
According to a preferred embodiment, the mood stabilising agent and the antidepressant or antipsychotic agent are present in the form of pills. The sustained-release agent can be provided as a transparent capsule.
The technical scheme has the advantages that: to ensure that the pattern on the medicament is recognizable and that the colour is stable during restoration, mood stabilising and antidepressant or antipsychotic agents can be solid pellets. The sustained-release drug can be in the form of a transparent, white, black or gray capsule due to the color and non-pattern arrangement of the sustained-release drug, and the capsule can contain a liquid or solid drug inside. The slow release medicament in the form of capsule makes the difference of the three medicaments more obvious due to the difference characteristics of the existing state and the color of the slow release medicament and the mood stabilizer and the antidepressant or antipsychotic medicament.
According to a preferred embodiment, the pharmaceutical composition can comprise a mood stabilizer and an antidepressant or antipsychotic agent, based on the presence of a rapid-cycling bipolar disorder disease.
The technical scheme has the advantages that: the bipolar disorder diseases include bipolar disorder diseases, bipolar disorder diseases and rapid-cycling bipolar disorder diseases. The first-class bipolar affective disorder disease and the second-class bipolar affective disorder disease are distinguished based on the expression and the morbidity degree of the manic period, but both have a rest period for keeping a normal affective state after the end of a cycle of affective change, but the rapid-cycle bipolar affective disorder disease is more expressed as interval attack of the manic period and a depressive period and has no maintenance period of the normal affective state. In the case of the rapid-cycling bipolar disorder, there is no intermittent phase, and thus it is necessary to administer a mood stabilizer and an antidepressant or antipsychotic agent in alternate cycles of manic and depressive cycles, and thus patients with the rapid-cycling bipolar disorder need to administer mood stabilizers and antidepressant or antipsychotic agents of different color systems.
According to a preferred embodiment, the reminder system for administration of a pharmaceutical composition for use in coordination with the onset cycle of bipolar disorder can be provided with at least three reservoirs having an outer surface matching the color system of the pharmaceutical composition. The medicine groove contains sealed and opens two kinds of states, through system control and the patient effect when to the operation of intelligence suggestion system of taking medicine realize the change between two kinds of states.
The technical scheme has the advantages that: the prior art drug storage systems do not distinguish between different colored pills and do not take into account psycho-logical interventions of psycho-psychology on bipolar patients during their daily maintenance. The technical scheme adopts an intelligent medicine taking prompt system which is matched with the colors of pills to guide a patient to take medicine based on the arrangement of the pills with different color systems. The system carries out double insurance setting through the induction of the medicine box for operating the medicine storage of the patient and the intelligent judgment of the system on the state of the medicine box, so that the patient can correctly take the medicine, and the doctor provides a double-diagnosis suggestion for the patient based on the judgment and the analysis of the medicine taking action of the patient.
An intelligent medicine taking prompting method realizes storage and taking of different kinds of medicines by using an intelligent medicine taking prompting system.
Drawings
FIG. 1 is a 24-phase color chart;
fig. 2 is a flow chart of one embodiment of an intelligent medication box of the present invention.
Detailed Description
The technical solution of the present invention is further explained by the following embodiments. It should be understood by those skilled in the art that the examples are only for the understanding of the present invention and should not be construed as the specific limitations of the present invention.
Example 1
The pharmaceutical composition for treating bipolar disorder patients comprises three dosing windows. The dosing window comprises a mood stabilizer and/or an antidepressant or antipsychotic agent. Mood stabilizer is used for regulating mood stabilization and neurotransmitter of patients in manic or hypomanic stage. Lithium carbonate can be used for patients with high mood and low mental skills but without aggression. Valproate (sodium valproate, magnesium valproate) is often used for patients with dysphoria, irritation, or even aggressive behavior. Patients in the depressed cycle comprise two types, one is a depressed mood, developing depressive illness; a patient with mental problems accompanied by depressed mood, such as hallucinations and cognitive impairment. For the former, lamotrigine (libitone, Lamictal), quetiapine (Seroquel), compound olanzapine/fluoxetine hydrochloride capsule (Symbyax) or olanzapine (Zyprexa) are generally used. For the latter, clozapine or risperidone is taken in combination with one of lamotrigine, quetiapine, a compound olanzapine/fluoxetine hydrochloride capsule, olanzapine, or the like.
The dosing window also includes a rest period for the rest period. Since patients exhibit normotia during the intermission period, it is common to administer a sustained release agent to prevent the beginning of the next cycle of anorgasmia in advance. The sustained release agent can be set based on mania or depression at the beginning of the next cycle.
Further, since the patient spends most of their time in the manic and depressive cycles, the medication taken during the different cycles is differentiated. The outer surface of the coat of the mood stabilizer is partially or completely provided with a cyan sea pattern with a color of 5 PB. The outer surface of the outer cover of the antidepressant or antipsychotic agent is provided with a red sun pattern with the color of 7.5R. The slow release preparation is a transparent capsule with transparent liquid wrapped inside.
Example 2
Treatment of bipolar affective patients is mostly lengthy and therefore physicians will recommend intensive care and regular follow-up in familiar environments such as home. The problem arises that when the guardian cannot supervise the patient at the 24-hour time, the patient takes the medicine regularly and quantitatively, especially when the patient is in a manic or depressive period to have an idea of resisting the taking of the medicine. Based on the existence of the problems, a plurality of medicine boxes for giving medicine taking prompts are generated in the prior art, but the medicine boxes are not suitable for being independently used by people with certain abnormal mental states due to the universal design.
The invention designs an intelligent medicine box which can be suitable for storing medicines with different color systems.
According to a preferred embodiment, fig. 2 is a flow chart of an embodiment of the intelligent medicine box of the present invention. After a patient in a disease state enters a hospital for a doctor, the hospital wears a patient monitoring bracelet on the wrist of the patient for monitoring the real-time state of the patient, and the patient monitoring bracelet can contain abnormal languages such as 'one mushroom' and abnormal behaviors such as 'appearing on the ground in a squatting or lying posture' based on physiological indexes and behavior states of the patient. When a patient in a disease state of manic cycle or depression cycle enters a consulting room for a diagnosis, a doctor holding the data reading and writing equipment uses the data reading of the monitoring bracelet as a diagnosis basis to perform inquiry or test table test, so as to confirm whether the patient has bipolar affective disorder.
After the patient is confirmed to have the bipolar affective disorder disease, the doctor selects the medicine through the hospital inquiry system, processes the bracelet and the intelligent medicine box which are used for serving the patient through the data read-write equipment carried by the doctor, and establishes the information transmission channel between the intelligent medicine box and the bracelet and between the intelligent medicine box and the guardian terminal.
According to a preferred embodiment, when the intelligent medicine box begins to serve the patient, the system for activating the intelligent medicine box allows the doctor to enter the allocation of the relevant parameters through the data read-write equipment carried by the doctor. It is worth noting that parameter adjustment can only be performed by a data read-write device of a doctor. The parameter contents of the deployment comprise: the type of the medicine, the storage position of the medicine, the medicine taking time, the medicine taking weight of each time and the abnormal behavior alarm of the patient. Based on the classification of doctors in different periods of the patient to the medicine taking information in different periods, the guardian can switch between the manic period medicine taking and the depressive period medicine taking based on the monitoring of different states of the patient.
The medical staff configures the intelligent medicine box of the patient according to the diagnosis result analyzed and determined by the data reading and writing device (which may include the above-mentioned medicine distribution and medicine taking information); when a patient takes medicine by using the intelligent medicine box, the intelligent medicine box generates verification information related to medicine taking information by collecting operation behaviors of the patient on the intelligent medicine box and temporarily storing the operation behaviors in the intelligent medicine box according to a time-related mode. For example, the verification information generated by the smart pill box may be generated based on patient medication behavior data obtained by monitoring patient medication behavior, which may be read by a data reading device at the doctor's site so that the doctor may obtain the patient medication behavior data and the verification information related to the medication administration information. After obtaining the medicine taking behavior data of the patient and the verification information related to the medicine taking information, the doctor can know the current mental state of the patient by combining the current clinical manifestation of the patient for the double-time clinical consultation and the secondary mental evaluation result, thereby judging the progress degree of the patient's condition.
According to a preferred embodiment, when the patient is in manic phase, when the patient utilizes intelligent medicine box to take medicine, the intelligence medicine box can play the music of releiving at the settlement time and remind the patient to carry out the medicine and intake, especially, the location information of bracelet is received and patient's position is judged to intelligent medicine box after the music broadcast, when the intelligence medicine box detects that the patient of wearing the bracelet does not produce the displacement that is close to intelligent medicine box, the voice prompt of taking medicine can be reported to the intelligence medicine box. Further, the intelligent medicine box sends the alarm of not taking medicine to the guardian terminal when the bracelet that detects the patient and wear finds that the patient still does not produce the tendency of taking medicine. Receive the suggestion at the patient, carry the bracelet that can monitor the patient and be close to intelligent medicine box and when taking the medicine box, the instruction that the pressure receiving sound that the medicine box produced based on the touching stopped. The medicine boxes with different color systems contain medicines which are taken by patients in different periods. The medicine for hermetically containing the 5PB cyan sea pattern for treating mania stage is placed in the small medicine box with the 5PB cyan sea pattern on the outer surface, which corresponds to the medicine setting. Preferably, the set small medicine box for storing the medicine to be taken can be used for giving a medicine type selection taking prompt in a vibration mode, a light flashing mode and the like. The change of relative position between action orbit, bracelet and the intelligent medicine box that intelligence medicine box can record the bracelet to judge the little medicine box that the patient selected, and record the action information of taking medicine in-process patient. The action information contains the voice of the patient, the position change of the intelligent medicine box when holding the intelligent medicine box, the relative position between the bracelet and the intelligent medicine box, and the medicine weight change of the small medicine box in the intelligent medicine box.
According to a preferred embodiment, the intelligent cartridge collects the patient's operational behavior on the intelligent cartridge. The intelligent medicine box stores the operation behaviors in an intelligent medicine box storage area in a data information mode along the time track sequence. In the event that an operational behavior associated with medication intake is determined based on the data information analysis, the intelligent pill box generates verification information that is correlated with the medication intake information of the patient. The information of single medicine taking is stored in the storage area as a set, the intelligent medicine box performs intersection processing on the set of the medicine taking information, and when the set of abnormal behavior quantity presented in the intersection is larger than the threshold value of abnormal behavior quantity set by a doctor in the intelligent medicine box, the intelligent medicine box in a locked state sends a re-diagnosis suggestion to a guardian in a mode of transmitting the analysis result of the abnormal behavior information of the patient to the guardian terminal of the guardian who is not accompanied by the patient. The intelligent medicine box can judge whether the guardian accompanies the patient through whether the positioning guardian terminal exists in the signal detection range. When the intelligent medicine box judges that the abnormal behavior of the patient does not conform to the behavior state displayed by the state of illness of the current bipolar affective disorder, the intelligent medicine box can be automatically locked so as to prevent the problem of drug poisoning caused by violent damage to the medicine box and mistaken administration of the medicine under the action of over-excitation of the patient. For example, when a patient is in a manic stage and the condition is aggravated, the patient can perform data collection of improper operations such as beating, violently dismantling or trying to continuously open a cover storing a current non-taking medicine on the intelligent medicine box prompting the patient to take medicine based on the current abnormal state of the patient. The intelligent medicine box which feels abnormal state change collects behavior operation of the patient and stores the behavior operation in a storage area in a collection mode. When the intelligent medicine box judges that the intersection quantity of the abnormal behaviors in the data set exceeds the abnormal behavior quantity threshold set by a doctor, the intelligent medicine box generates an abnormal behavior report and sends the abnormal behavior report to the guardian terminal in a short message mode. The abnormal behavior report content comprises the recorded abnormal behavior form, the recorded abnormal behavior frequency, the threshold value of the abnormal behavior preset by a doctor, the result exceeding the threshold value and the suggestion of the patient carrying the patient for the further diagnosis.
According to a preferred embodiment, the collection logic for overlapping sets of data for determining abnormal patient behavior can also be stored in the memory area of the intelligent pill boxes in the order of abnormal patient behavior to the intelligent pill boxes.
It should be noted that the above-mentioned embodiments are exemplary, and that those skilled in the art, having benefit of the present disclosure, may devise various arrangements that are within the scope of the present disclosure and that fall within the scope of the invention. It should be understood by those skilled in the art that the present specification and figures are illustrative only and are not limiting upon the claims. The scope of the invention is defined by the claims and their equivalents.
Claims (10)
1. An intelligent medication intake cue system comprising a pharmaceutical composition for bipolar disorder and a pharmaceutical composition administration cue system for coordinating the onset cycle of bipolar disorder, wherein the pharmaceutical composition comprises one or more of three dosage windows comprising a mood stabilizer for manic or manic, an antidepressant or antipsychotic agent for the depressive phase or a sustained release agent for the intermittent phase,
it is characterized in that the preparation method is characterized in that,
the intelligent medicine taking prompting system provides medicine taking suggestions with the distinguishing characteristics of the color system of the mood stabilizer, the antidepressant or antipsychotic medicament and the sustained-release medicament for a user in an image mode, wherein the taking sequence of the mood stabilizer, the antidepressant or antipsychotic medicament and the sustained-release medicament forms an execution condition of a message driving type medicine taking suggestion processed and expanded by the intelligent medicine taking prompting system around the distinguishing characteristic color system as information.
2. The system of claim 1, wherein the mood stabilizer, partially or wholly coated with an edible coating comprising one or more of color systems P, PB, B, BG or G is provided on the outer surface to counteract the psychological conflict of taking medications during manic phases.
3. The intelligent medication prompting system of claim 1 or 2, wherein the overcoat of mood stabilising agents comprises a pattern for a plateau mood consisting of one or more of the colour families P, PB, B, BG or G based on its disposition against a manic or manic mood of the patient.
4. The intelligent medication prompting system of one of the preceding claims, wherein the antidepressant or antipsychotic agent is used for fighting negative mood of taking medicine, and the external surface of the agent is provided with a coat formed by one or more colors of GY, Y, TR, R or RP.
5. The intelligent medication prompting system of one of the preceding claims, wherein the overcoat of the anti-depressive or anti-psychotic medicament sets a pattern for mood enhancement or attention based on which one or more of the color systems GY, Y, TR, R or RP is set for a patient's depressed or fantasy mood.
6. The intelligent medication prompting system of one of the preceding claims, wherein the slow release agent, the slow release outer membrane of which is set to be transparent, white, black or neutral color tone with certain gray scale in a manner distinguishable from the mood stabilizer and the antidepressant or antipsychotic agent.
7. The intelligent medication prompting system of one of the preceding claims, wherein the mood stabilizer and the antidepressant or antipsychotic agent are in the form of pills.
8. The intelligent drug prompting system of one of the preceding claims, wherein the slow release medicament can be provided as a transparent capsule.
9. The intelligent drug cue system of one of the preceding claims wherein the pharmaceutical composition can comprise a mood stabilizer and an antidepressant or antipsychotic agent based on the presence of the rapid-cycling bipolar disorder disease.
10. An intelligent medicine taking prompting method is characterized in that different kinds of medicines are stored and taken by using the intelligent medicine taking prompting system as any one of claims 1 to 9.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110999931.7A CN113662858B (en) | 2021-08-25 | 2021-08-25 | Intelligent medicine taking prompt system and method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110999931.7A CN113662858B (en) | 2021-08-25 | 2021-08-25 | Intelligent medicine taking prompt system and method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113662858A true CN113662858A (en) | 2021-11-19 |
| CN113662858B CN113662858B (en) | 2024-03-29 |
Family
ID=78547223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110999931.7A Active CN113662858B (en) | 2021-08-25 | 2021-08-25 | Intelligent medicine taking prompt system and method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113662858B (en) |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101708147A (en) * | 2009-09-29 | 2010-05-19 | 沈阳红旗制药有限公司 | Electronic medicament administration reminder applied to tuberculosis |
| CN103201742A (en) * | 2010-08-16 | 2013-07-10 | 曼雷克斯股份有限公司 | Detecting non-compliance patterns in prescribed medication doses |
| CN105668016A (en) * | 2016-03-15 | 2016-06-15 | 王丽 | Medicine box prompting chronic patient to accurately take medicine |
| CN105872105A (en) * | 2016-06-12 | 2016-08-17 | 深圳市亿蟠技术有限公司 | Intelligent dosing management system and operating method thereof |
| CN110711139A (en) * | 2019-11-13 | 2020-01-21 | 王峰 | Intelligent medicine box and intelligent medicine taking control system and method |
| CN111544397A (en) * | 2020-06-11 | 2020-08-18 | 江苏颐海药业有限责任公司 | Preparation method of cartoon type medicine for enhancing immunity of children |
| CN111840082A (en) * | 2020-07-08 | 2020-10-30 | 东莞市康益医疗科技有限公司 | Medicine taking method and device based on partitioned medicine box |
| CN212662251U (en) * | 2020-08-14 | 2021-03-09 | 马永春 | Intelligent medicine box |
| CN213199255U (en) * | 2020-05-25 | 2021-05-14 | 淮安市第三人民医院 | Colored medicine business card convenient for patient to remember |
| CN113662857A (en) * | 2021-08-25 | 2021-11-19 | 首都医科大学宣武医院 | Medicine storage system and method |
-
2021
- 2021-08-25 CN CN202110999931.7A patent/CN113662858B/en active Active
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101708147A (en) * | 2009-09-29 | 2010-05-19 | 沈阳红旗制药有限公司 | Electronic medicament administration reminder applied to tuberculosis |
| CN103201742A (en) * | 2010-08-16 | 2013-07-10 | 曼雷克斯股份有限公司 | Detecting non-compliance patterns in prescribed medication doses |
| CN105668016A (en) * | 2016-03-15 | 2016-06-15 | 王丽 | Medicine box prompting chronic patient to accurately take medicine |
| CN105872105A (en) * | 2016-06-12 | 2016-08-17 | 深圳市亿蟠技术有限公司 | Intelligent dosing management system and operating method thereof |
| CN110711139A (en) * | 2019-11-13 | 2020-01-21 | 王峰 | Intelligent medicine box and intelligent medicine taking control system and method |
| CN213199255U (en) * | 2020-05-25 | 2021-05-14 | 淮安市第三人民医院 | Colored medicine business card convenient for patient to remember |
| CN111544397A (en) * | 2020-06-11 | 2020-08-18 | 江苏颐海药业有限责任公司 | Preparation method of cartoon type medicine for enhancing immunity of children |
| CN111840082A (en) * | 2020-07-08 | 2020-10-30 | 东莞市康益医疗科技有限公司 | Medicine taking method and device based on partitioned medicine box |
| CN212662251U (en) * | 2020-08-14 | 2021-03-09 | 马永春 | Intelligent medicine box |
| CN113662857A (en) * | 2021-08-25 | 2021-11-19 | 首都医科大学宣武医院 | Medicine storage system and method |
Non-Patent Citations (1)
| Title |
|---|
| 吕洛矜: "《说吧，医生》", 31 January 2015, 上海三联书店, pages: 194 - 195 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113662858B (en) | 2024-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3213184U (en) | Eye drop dispenser | |
| Nesse | Evolutionary psychology and mental health | |
| KR20120007267A (en) | A pill box and a method for managing an administration of a medication | |
| Heninger et al. | Personality factors in variability of response to phenothiazines | |
| Keeley et al. | Anxiety disorders in youth | |
| US20200395122A1 (en) | Health management system and program for same | |
| Reed et al. | An analysis of the concept of self-neglect | |
| Gackenbach et al. | Lucid dreaming frequency in relation to vestibular sensitivity as measured by caloric stimulation | |
| JP2015505481A (en) | Method and apparatus for continuous measurement of intraocular pressure | |
| CN113662858A (en) | Intelligent medicine taking prompting system and method | |
| O'Dell et al. | Standardized assessment instruments for minimally-responsive, brain-injured patients | |
| Loke | The effects of caffeine and automaticity on a visual information processing task | |
| Wolfson et al. | Clozapine audit: What do patients and relatives think? | |
| Schmidt et al. | Differential effects of safety in extinction of anxious responding to a CO₂ challenge in patients with panic disorder. | |
| Case et al. | A Practical Guide to Supporting People with Epilepsy | |
| DeGiorgio et al. | Consciousness, coma, and the vegetative state: physical basis and definitional character | |
| Seeman | Symptoms of schizophrenia: normal adaptations to inability | |
| Kopecky et al. | Agitation: conceptualization, measurement, and treatment | |
| Way et al. | An integrative framework of supervisor responses to workgroup conflict | |
| Anderson | Workbook for Mosby's Textbook for Medication Assistants E-Book: Workbook for Mosby's Textbook for Medication Assistants E-Book | |
| Owczarek et al. | Personality profiles of patients with psychogenic nonepileptic seizures | |
| Kutscher | Children with seizures: A guide for parents, teachers, and other professionals | |
| Byrne et al. | Antidepressant medication in the outpatient treatment of depression: Guide for nonmedical psychotherapists. | |
| Wesson | Medical treatment for complications of polydrug abuse | |
| Hickey | The role of disgust in Body Dysmorphic Disorder: A preliminary investigation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |